Maiyue Technology (02501) advanced about 17% to an intraday high of HK$1.795, with turnover of 1.874 million shares worth HK$3.002 million, according to ETNet.

The stock has climbed for four consecutive sessions, rising 28.2% over that stretch. Its active buy-to-sell ratio stood at 91:9, with net active buying of HK$2.4667 million.

The Digital Asset Exchange Association (DAXA) of South Korea has identified four foreign virtual-asset operators that have not been officially reported to authorities, and it has requested a police investigation.

News1 reported the development, while Foresight News notes that among the named exchanges are Big One and CoinMy.

Hyperliquid Strategies has expanded its equity facility with Chardan Capital Markets from $1 billion to $2.5 billion, increasing its capacity to raise capital through share issuances tied to its HYPE-focused treasury strategy. The company also said it amended the October 2025 Chardan Equity Facility purchase agreement to raise the aggregate gross purchase price of newly issued common stock.

Under the agreement, Hyperliquid can periodically instruct Chardan to purchase shares at pricing, trading volume, and other conditions, after which Chardan may resell the shares in the public market.

The larger facility offers more potential funding, but any use of it would issue additional shares and could dilute existing shareholders.

The $2.5 billion figure represents maximum capacity rather than funds already raised.

Hyperliquid Strategies previously reported raising $647 million through the facility and expanding its treasury to about 29.3 million HYPE tokens.

The expansion comes amid renewed market interest in Hyperliquid. HYPE rose more than 20% in August after remarks from former U.S. president Donald Trump that the CFTC chair was working to bring the decentralized trading platform into the United States in a fully compliant and legal fashion. Hyperliquid Strategies shares rose 30.4% following those remarks.

Despite sharing the protocol's name and holding its native token, the company says it remains independent and has no formal affiliation with Hyperliquid.

Lithium-related shares moved lower on Tuesday, with CATL (03750) down 3.9% to HK$569, Ganfeng Lithium (01772) falling 6.1% to HK$38.02 and Tianqi Lithium (09696) down 4% to HK$36.06, according to ETNet.

The main carbon lithium futures contract declined for a second consecutive session, slipping 3.54% to RMB 154,300 after an intraday drop of up to 4%.

The Hang Seng Index was at 25,076, down 253 points or 1%, with main-board turnover surpassing HK$114.7 billion.

The Hang Seng China Enterprises Index declined 1.1% to 8,368, while the Hang Seng Tech Index dropped 1.5% to 4,482.

Elon Musk, founder of xAI, stated on X that Grok version 4.7 is expected to launch within the next 10 days.

ChainCatcher reported that no further specifics about the update were provided.

UBS reduced MINISO's target price to $14 from $19.84 and kept a Buy rating, according to ETNet.

The bank noted MINISO delivered 17% year-on-year revenue growth to RMB 5.81 billion in the second quarter, while adjusted net profit declined 10% to RMB 588 million, in line with the company’s profit warning. Revenue by segment rose 23% in China, 9% overseas, and 17% from TOP TOY.

UBS said overseas growth cooled as distributor sales fell, led by Asia-Pacific and Latin America markets. The higher-margin distributor model contributed less revenue, which helped push the second-quarter adjusted operating margin down by about three percentage points year over year.

Valuation-wise, the stock trades at eight times forecast 2026 adjusted net profit and seven times forecast 2027 adjusted net profit, a level UBS says largely reflects ongoing pressure from overseas distributor channel restructuring. Management expects further distributor store closures and margin pressure in the near term, but notes that downside risks appear priced in. Domestic operations remain resilient and should support earnings via store upgrades and productivity gains.

UBS added that management has slowed store expansion, which should ease operating expense pressure and bolster profitability. It projects overseas business to account for more than 40% of group profit in 2025, declining to below 30% in its 2026 forecast.

BoJ Policy Board member Hajime Takata reaffirmed his view that rate increases should be flexible, weighing overseas conditions against the degree of easing in domestic financial conditions to curb price pressures.

He spoke in Sapporo, Hokkaido, during a gathering with local business leaders on Wednesday.

During the July 30-31 policy meeting, Takata had proposed lifting the policy rate by 25 basis points to 1.25% and was the sole dissenter against keeping rates near 1%.

Bank of Japan board member Hajime Takata, regarded as one of the central bank's more hawkish policymakers, reiterated his call for nimble rate hikes to keep inflation from moving above the target, Bloomberg reports.

Takata argues that small, timely increases are necessary to prevent upward deviations in prices without derailing growth.

BeiGene Biotech-B (02315) rose more than 11% to HK$63.65, moving above its 20-day moving average of HK$62.785, according to ETNet data.

The trading volume reached 831,000 shares, with a turnover of HK$50.78 million.

The gain marks two consecutive sessions higher, bringing the total increase to 12.9%.

Jin10 reported that Bank of Japan Governor Kazuo Ueda plans to monitor several factors that could influence policy decisions.

He will focus on the Middle East conflict, demand for artificial intelligence, the impact of foreign-exchange movements on the economy, and the role of prices in policy guidance.